U.S. Markets closed

Viva Biotech Holdings (1873.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
5.170-0.290 (-5.31%)
As of 04:08PM HKT. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.460
Bid5.170 x N/A
Ask5.190 x N/A
Day's Range5.090 - 5.600
52 Week Range4.440 - 11.640
Avg. Volume5,511,048
Market Cap9.952B
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
Earnings DateMar 30, 2021
Forward Dividend & Yield0.02 (0.25%)
Ex-Dividend DateJun 16, 2021
1y Target EstN/A
  • PR Newswire

    Viva Biotech Announced 2021 Interim Results

    On August 30, 2021, Viva Biotech Holdings (1873.HK) announced that during the period ended June 30, 2021 (the "Reporting Period"), revenue of the Group increased significantly to RMB1,026.5 million from RMB197.6 million for the corresponding period last year, representing a YoY increase of approximately 419.5%, gross profit increased substantially from RMB100.1 million for the corresponding period last year to RMB316.3 million, representing a YoY increase of 216.0%. The adjusted net profit of th

  • PR Newswire

    Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci

    Viva Biotech (01873.HK) declared today that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics. Totient is a biotech company, harnessing human immune responses to identify novel antibodies and their therapeutic targets. This acquisition adds antibody and target discovery technology to AbSci's platform for therapeutic protein design and biomanufacturing optimization.

  • PR Newswire

    Viva Biotech and BioMap Reached a Strategic Collaboration Agreement, To Jointly Accelerate the Early Drug Discovery through AI Technology

    Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou. The conference is aiming to unite with biotech and IT industry partners to create a multi-party integrated industrial ecosystem, and realize AI's comprehensive empowerment in the field of biotechnology.